Journal of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회지)

Korean Society of Radiopharmaceuticals and Molecular Probes (대한방사성의약품학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of [124I]IBTPB as a PET Imaging Agent for BNCT Drug Development

  • Iqra Bibi (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Kyo Chul Lee (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Kwang Il Kim (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Ji-Ae Park (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Sajid Mushtaq (Division of Applied RI, Korea Institute of Radiological & Medical Sciences (KIRAMS)) ;
  • Soyeon Kim (Leading Research Center of Total Solution for Osteoporosis Treatment, Chonnam National University)
  • Received : 2024.11.28
  • Accepted : 2024.12.09
  • Published : 2024.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Boron neutron capture therapy (BNCT) is a precision treatment technology that selectively damages boron-accumulating cells. To apply BNCT to brain tumors, it is essential to develop boron drugs with both high blood-brain barrier (BBB) penetration and tumor-selective accumulation. Additionally, the development of imaging agents capable of visualizing the biodistribution of boron drugs in vivo is critical. In this study, [124I]IBTPB was synthesized by radiolabeling the boron-containing benzothiazole compound (BTPB). The tumor selectivity and biodistribution of [124I]IBTPB were evaluated to assess its potential as a diagnostic agent for visualizing the in vivo behavior of BTPB using PET imaging. BTPB and [124I]IBTPB exhibited differences in their in vivo behavior due to structural differences, administration methods, and dosages. However, these findings provide valuable insights into the challenges that must be addressed in the development of BNCT agents (diagnostics and therapeutics), thereby contributing to the advancement of future BNCT drug development.

Keywords

Acknowledgement

이 논문은 이 논문은 한국연구재단 학문후속세대양성지원사업 (2021R1A6A3A01086709)과 과학기술정보통신부 한국원자력의학원 연구운영비지원사업(50462-2024)에 의하여 이루어졌으며 다른 이해관계는 없음을 밝힙니다.